Immunotherapy prospects in the treatment of lung cancer and mesothelioma

被引：21

作者：

Aerts, Joachim G. ^{[1
,2
]}

Lievense, Lysanne A. ^{[1
]}

Hoogsteden, Henk C. ^{[1
]}

Hegmans, Joost P. ^{[1
]}

机构：

[1] Erasmus MC Canc Inst, Dept Pulm Med, Ee2253a,Dr Molewaterpl 50, NL-3015 GD Rotterdam, Netherlands

[2] Amphia Hosp Breda, Dept Pulm Dis, Breda, Netherlands

来源：

TRANSLATIONAL LUNG CANCER RESEARCH | 2014年 / 3卷 / 01期

关键词：

Non small cell lung cancer (NSCLC); immunotherapy; immune checkpoint antibodies;

D O I：

10.3978/j.issn.2218-6751.2013.11.04

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A very recent finding is the role of immune activation in cancer. The assumption that stimulating the patient's immune system to attack tumors is a valuable treatment option in malignant diseases has gained more acceptance. However the high immunosuppressive effects caused by the tumor limits this beneficial effect. There is a delicate balance between immunoactivation and immunosuppression in a patient. Especially in non small cell lung cancer (NSCLC), the role of immunosuppressive cells hampering immune activation is high. But also in small cell lung cancer (SCLC) and mesothelioma immunosuppressive activity is high. This is suggested to be related to the type of tumor, advanced stage of the disease, and the tumor load. In this review, we provide an overview of the progress and challenges in the immunotherapeutic approaches in lung cancer. We conclude with the concept that immunotherapy in thoracic malignancies must be tailored made to the balance of the immune system.

引用

页码：34 / 45

页数：12

共 128 条

[1]

Aerts JG, 2013, J THORAC ONCOL, V8, pS764

[2] Tumor-Specific Cytotoxic T Cells Are Crucial for Efficacy of Immunomodulatory Antibodies in Patients with Lung Cancer [J].

Aerts, Joachim G. ;

Hegmans, Joost P. .

CANCER RESEARCH, 2013, 73 (08) :2381-2388

[3] T cell anergy and costimulation [J].

Appleman, LJ ;

Boussiotis, VA .

IMMUNOLOGICAL REVIEWS, 2003, 192 (01) :161-180

[4] Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: AVAPERL (MO22089) [J].

Barlesi, Fabrice ;

Scherpereel, Arnaud ;

Rittmeyer, Achim ;

Pazzola, Antonio ;

Tur, Neus Ferrer ;

Kim, Joo-Hang ;

Ahn, Myung-Ju ;

Aerts, Joachim G. J. V. ;

Gorbunova, Vera ;

Vikstrom, Anders ;

Wong, Elaine K. ;

Perez-Moreno, Pablo ;

Mitchell, Lada ;

Groen, Harry J. M. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (24) :3004-+

[5] Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer [J].

Bass, KK ;

Mastrangelo, MJ .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 1998, 47 (01) :1-12

[6] Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer [J].

Belani, Chandra P. ;

Nemunaitis, John J. ;

Chachoua, Abraham ;

Eisenberg, Peter D. ;

Raez, Luiz E. ;

Cuevas, J. Daniel ;

Mather, Cecile B. ;

Benner, Rebecca J. ;

Meech, Sandra J. .

CANCER BIOLOGY & THERAPY, 2013, 14 (07) :557-563

[7] Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2/BCG in responding patients with limited disease small-cell lung cancer [J].

Bottomley, Andrew ;

Debruyne, Channa ;

Felip, Enriqueta ;

Millward, Michael ;

Thiberville, Luc ;

D'Addario, Giannicola ;

Rome, Lisa ;

Zatloukal, Petr ;

Coens, Corneel ;

Giaccone, Giuseppe .

EUROPEAN JOURNAL OF CANCER, 2008, 44 (15) :2178-2184

[8] Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer [J].

Brahmer, Julie R. ;

Tykodi, Scott S. ;

Chow, Laura Q. M. ;

Hwu, Wen-Jen ;

Topalian, Suzanne L. ;

Hwu, Patrick ;

Drake, Charles G. ;

Camacho, Luis H. ;

Kauh, John ;

Odunsi, Kunle ;

Pitot, Henry C. ;

Hamid, Omid ;

Bhatia, Shailender ;

Martins, Renato ;

Eaton, Keith ;

Chen, Shuming ;

Salay, Theresa M. ;

Alaparthy, Suresh ;

Grosso, Joseph F. ;

Korman, Alan J. ;

Parker, Susan M. ;

Agrawal, Shruti ;

Goldberg, Stacie M. ;

Pardoll, Drew M. ;

Gupta, Ashok ;

Wigginton, Jon M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) :2455-2465

[9] The Role of Tumor-Infiltrating Immune Cells and Chronic Inflammation at the Tumor Site on Cancer Development, Progression, and Prognosis Emphasis on Non-small Cell Lung Cancer [J].

Bremnes, Roy M. ;

Al-Shibli, Khalid ;

Donnem, Tom ;

Sirera, Rafael ;

Al-Saad, Samer ;

Andersen, Sigve ;

Stenvold, Helge ;

Camps, Carlos ;

Busund, Lill-Tove .

JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (04) :824-833

[10] Reactivity of monoclonal antibodies with ganglioside antigens in human small cell lung cancer tissues [J].

Brezicka, T ;

Bergman, B ;

Olling, S ;

Fredman, P .

LUNG CANCER, 2000, 28 (01) :29-36

← 1 2 3 4 5 6 7 8 9 10 →